Nama Insights

Qiagen (QGEN)

Healthcare · Diagnostics Research · NYSE

Qiagen (QGEN) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $10.25B, a trailing price-to-earnings ratio of 20.6 and a free-cash-flow yield of 4.3%. Over the most recent reported fiscal year, revenue grew 5.7% and free cash flow per share fell 11.1%. Nama's AI scorecard rates it Buy, 6.8 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Buy · 6.8/10
Positive, at the low end of Buy. As of Nov 20, 2026.
Momentum
Middle · +9.5% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-17.5%
How far the last close sits under the highest price of the past five years.
Market cap$10.25B
Trailing P/E20.6
Price / book3.0
Price / sales4.8
FCF yield4.3%
Dividend yield0.7%
Gross margin62.8%
Operating margin25.1%
Net margin18.2%
Revenue growth (YoY)+5.7%
Revenue growth (3-yr annual)-0.8%
EPS growth (YoY)+4.7%
FCF/share growth (YoY)-11.1%
Beta0.6
ExchangeNYSE
SectorHealthcare
IndustryDiagnostics Research

QGEN earnings

Next report: Feb 3, 2027 (Q4 2026, EPS estimate $0.66). Beat the EPS estimate in 1 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 3, 2026 $0.65 $0.63 +3.2% $547.87M
Q2 2026 Aug 4, 2026 $0.60 $0.60 +0.0% $535.04M
Q1 2026 May 5, 2026 $0.54 $0.54 +0.0% $492.32M
Q4 2025 Feb 4, 2026 $0.62 $0.62 +0.0% $540.42M

QGEN analyst price target

Median target $52.00 from 11 analysts, ranging $40.00 – $53.00.

Diagnostics Research peers

TickerCompanyMarket capP/E
TMO Thermo Fisher Scientific $255.19B 27.9
DHR Danaher $160.10B 27.3
WAT Waters $89.71B 31.7
IDXX IDEXX Laboratories $54.33B 46.5
A Agilent Technologies $49.44B 28.9
NTRA Natera $42.04B —
IQV IQVIA $41.29B 19.6
MTD Mettler-Toledo International $33.93B 36.8
Explore live QGEN data on Nama Insights →

QGEN FAQ

Is QGEN a buy?
Nama's AI scorecard currently rates Qiagen Buy (6.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is QGEN's P/E ratio?
Qiagen trades at a trailing price-to-earnings ratio of 20.6.
When does QGEN report earnings?
Qiagen's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $0.66.
What is the QGEN price target?
The median analyst price target from 11 analysts is $52.00, with a range of $40.00 – $53.00.
Is QGEN Shariah compliant?
Nama's AAOIFI-style screen reads Qiagen as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does QGEN pay a dividend?
Yes — Qiagen's dividend yield is 0.7%.